Correlation between ABO blood type, susceptibility to SARS-CoV-2 infection and COVID-19 disease severity: A systematic review

Soares, Danyela Martins Bezerra; Araújo, David Augusto Batista Sá; Souza, Jorge Luiz de Brito de; Maurício, Rebeca Bessa; Soares, Emanuela Martins Bezerra; Neto, Franklin de Castro Alves; Pinheiro, Maria Suelly Nogueira; Gama, Vitor Carneiro de Vasconcelos; Braga‐Neto, Pedro; Nóbrega, Paulo Ribeiro; Aragão, Gislei Frota

doi:10.1016/j.htct.2022.11.001

Cited by 4 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Literature data show different associations between blood groups and COVID‐19 infection. It has been shown that people with blood type A had a worse COVID‐19 prognosis compared to type O cases 16,17 . This issue has been described by the similarity between SARS‐CoV‐2 protein and blood groups ABO.…”

Section: Discussionmentioning

confidence: 99%

“…It has been shown that people with blood type A had a worse COVID-19 prognosis compared to type O cases. 16,17 This issue has been described by the similarity between SARS-CoV-2 protein and blood groups ABO. It is to say that when the virus infects a person belonging to blood group O, anti-A and anti-B Abs target the virus as the immune system response and thus it could prevent viral spread through the host cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

Sadat Larijani,

Javadi,

Eskandari

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

This study evaluated the possible effects of blood types on coronavirus disease (COVID‐19) vaccine immunogenicity and antibody (Ab) persistency. Five different vaccinated groups against COVID‐19 were investigated at Pasteur Institute of Iran from April 2021 to December 2022. Anti‐Spike IgG and neutralizing Ab rise were tracked on Day 21 as well as the humoral immune persistency assessment 180 after booster shots. Late adverse events up to 6 months after the booster dose were collected. The results showed that blood type A, led to a significantly higher anti‐Spike Ab rise in AstraZeneca primed recipients in comparison with Sinopharm primed ones in heterologous regimens (p: 0.019). Furthermore, blood type O was a great co‐effector in homologous AstraZeneca recipients regarding neutralizing Ab rise (0.013). In addition, blood type O led to a better anti‐Spike Ab persistency in the Sinopharm homologous group whereas type A had the best effect on neutralizing Ab durability in the same vaccine group. What is more, Rh‐positive individuals in AstraZeneca + PastoCovac Plus group had a higher rate of anti‐Spike Ab rise (p = 0.001). Neutralizing Ab rise was also induced in AstraZeneca homologous and heterologous regimens of Rh‐positive individuals significantly higher than Sinopharm primed cases. The present study showed the potential impact of blood types A/O and Rh‐positive on a better humoral immune responses and Ab persistency. It is proposed that blood type A and Rh‐positive could increase the Ab rise in AstraZeneca vaccinated individuals. Moreover, blood type O might be a better co‐effector of anti‐Spike Ab persistency in Sinopharm recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

Sadat Larijani,

Javadi,

Eskandari

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Initial reports from the onset of the pandemic indicated a link between COVID-19 severity and ABO blood groups [39], with subsequent research works reporting similar findings. In particular, blood group A patients were shown to exhibit both increased susceptibility to SARS-CoV-2 infection [38,[40][41][42][43][44][45][46][47][48][49][50][51] and increased illness severity [42,47,48,[52][53][54]. Increased infection susceptibility has also been reported for individuals of blood group AB [46,50], as well as for those of blood group B in addition to blood group A [47], while one study reported reduced susceptibility for individuals of the AB blood group [43].…”

Section: Abo Blood Groups and Secretor Status In Relation To Covid-19...mentioning

confidence: 99%

Investigating ABO Blood Groups and Secretor Status in Relation to SARS-CoV-2 Infection and COVID-19 Severity

Ferous,

Siafakas,

Boufidou

et al. 2024

JPM

View full text Add to dashboard Cite

The ABO blood groups, Lewis antigens, and secretor systems are important components of transfusion medicine. These interconnected systems have been also shown to be associated with differing susceptibility to bacterial and viral infections, likely as the result of selection over the course of evolution and the constant tug of war between humans and infectious microbes. This comprehensive narrative review aimed to explore the literature and to present the current state of knowledge on reported associations of the ABO, Lewis, and secretor blood groups with SARS-CoV-2 infection and COVID-19 severity. Our main finding was that the A blood group may be associated with increased susceptibility to SARS-CoV-2 infection, and possibly also with increased disease severity and overall mortality. The proposed pathophysiological pathways explaining this potential association include antibody-mediated mechanisms and increased thrombotic risk amongst blood group A individuals, in addition to altered inflammatory cytokine expression profiles. Preliminary evidence does not support the association between ABO blood groups and COVID-19 vaccine response, or the risk of developing long COVID. Even though the emergency state of the pandemic is over, further research is needed especially in this area since tens of millions of people worldwide suffer from lingering COVID-19 symptoms.

show abstract

“…5 Recently, the influence of blood groups on disease has extended to the COVID-19 pandemic. Meta-analyses concluded that those with blood group A have higher risk of infection with severe acute respiratory virus 2 (SARS-CoV-2) whereas blood group O is relatively protective [9][10][11][12] ; this has been extended to disease outcomes. [13][14][15] The evidence is equivocal concerning RhD antigen status, and a possible protective effect arising from lack of the RhD antigen against SARS-CoV-2 infection.…”

mentioning

confidence: 99%

Association of ABO and Rhesus blood groups with severe outcomes from non‐SARS‐CoV‐2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020–2022

Hathaway,

Qian,

King

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryDespite significant global morbidity associated with respiratory infection, there is a paucity of data examining the association between severity of non‐SARS‐CoV‐2 respiratory infection and blood group. We analysed a prospective cohort of adults hospitalised in Bristol, UK, from 1 August 2020 to 31 July 2022, including patients with acute respiratory infection (pneumonia [n = 1934] and non‐pneumonic lower respiratory tract infection [NP‐LRTI] [n = 1184]), a negative SARS‐CoV‐2 test and known blood group status. The likelihood of cardiovascular complication, survival and hospital admission length was assessed using regression models with group O and RhD‐negative status as reference groups. Group A and RhD‐positive were over‐represented in both pneumonia and NP‐LRTI compared to a first‐time donor population (p < 0.05 in all); contrastingly, group O was under‐represented. ABO group did not influence cardiovascular complication risk; however, RhD‐positive patients with pneumonia had a reduced odds ratio (OR) for cardiovascular complications (OR = 0.77 [95% CI = 0.59–0.98]). Compared to group O, group A individuals with NP‐LRTI were more likely to be discharged within 60 days (hazard ratio [HR] = 1.17 [95% CI = 1.03–1.33]), while group B with pneumonia was less likely (HR = 0.8 [95% CI = 0.66–0.96]). This analysis provides some evidence that blood group status may influence clinical outcome following respiratory infection, with group A having increased risk of hospitalisation and RhD‐positive patients having reduced cardiovascular complications.

show abstract

Correlation between ABO blood type, susceptibility to SARS-CoV-2 infection and COVID-19 disease severity: A systematic review

Cited by 4 publications

References 59 publications

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

Investigating ABO Blood Groups and Secretor Status in Relation to SARS-CoV-2 Infection and COVID-19 Severity

Association of ABO and Rhesus blood groups with severe outcomes from non‐SARS‐CoV‐2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020–2022

Contact Info

Product

Resources

About